This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Omega-3-acid ethyl esters oral

Updated 2 Feb 2023 | Omega-3 preparations


Oral formulations of omega-3-acid ethyl esters 90 comprising of eicosapentaenoic acid (EPA) ethyl ester and docosahexaenoic acid (DHA) ethyl ester.

Drugs List

  • eicosapentaenoic acid 460mg and docosahexaenoic acid 380mg capsules
  • OMACOR capsules
  • TEROMEG 1000mg capsules
  • Therapeutic Indications


    Adjunctive therapy to diet for the reduction of elevated triglycerides

    Adjuvant treatment to diet in endogenous hypertriglyceridaemia when dietary measures alone are insufficient to produce an adequate response:

    Type IV in monotherapy.

    Type IIb/III in combination with statins, when control of triglycerides using statins alone is insufficient.



    Initial treatment 2 capsules daily. If adequate response is not obtained, the dose may be increased to 4 capsules daily.


    Children under 18 years

    Precautions and Warnings

    Patients over 70 years
    Predisposition to haemorrhage
    Hepatic impairment
    Renal impairment

    Adjustment of anticoagulant dose may be necessary during concurrent therapy
    Not indicated for treatment of exogenous hypertriglyceridaemia (type 1)
    Contains soya or soya derivative
    Monitor hepatic function in patients with hepatic impairment
    Monitor patients receiving concurrent anticoagulants
    Advise patient to take after food to reduce gastro-intestinal disturbances

    Hepatic impairment
    It has been reported in some patients a small but important increase (within normal values) in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. AST and ALT levels should be monitored in patients with any signs of liver damage, in particular in patients taking high doses. There are no data showing an increased risk for patients with hepatic impairment.

    Pregnancy and Lactation


    Use omega-3-acid ethyl esters 90 with caution during pregnancy.

    The manufacturer does not recommend using omega-3-acid ethyl esters 90 during pregnancy unless clearly necessary. At the time of writing there is limited published information regarding the use of omega-3-acid ethyl ester 90 during pregnancy. Potential risks are unknown.


    Omega-3-acid ethyl esters 90 is contraindicated during breastfeeding.

    The manufacturer contraindicates the use of omega-3-acid ethyl esters 90 when breastfeeding. The presence of omega-3-acid ethyl esters 90 in human breast milk and the effect on exposed infants are unknown.

    Side Effects

    Abdominal distension
    Abdominal pain
    Gastro-intestinal disturbances
    Gastro-intestinal haemorrhage
    Gastroesophageal reflux disease
    Hepatic disorders
    Hypersensitivity reactions
    Increase in serum transaminases


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: December 2019.

    Reference Sources

    Summary of Product Characteristics: Omacor 1000mg soft capsules. Mylan. Revised July 2019.

    Summary of Product Characteristics: Teromeg 1000mg capsules. ADVANZ Pharma. Revised October 2019.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.